


### III. Remarks and Conclusion

Claims 32-35 and 64-67 are currently pending. Claims 1-31 and 36-63 have been cancelled without prejudice or disclaimer to pursue the Claims of Invention II, as defined by the Examiner. No estoppel. The cancellations made were not based on reasons related to patentability under 35 U.S.C. §§ USC 101, 102, 103 and/or 112. No estoppel should result from said cancellations. Further, the amendments are made to correct typographical errors. No limiting of the claim language has occurred and no estoppel should result. Applicants expressly reserve the right to pursue the non-elected subject matter in a divisional application.

In conclusion, Applicants reaffirm the election of Group II. Further, Applicants assert the Claims are in a condition for allowance and such action is respectfully requested. Should the Examiner determine an interview would best further the prosecution of the case, the Examiner is invited to contact the undersigned attorney at (302) 933-4034.

Respectfully Submitted,



William P. Ramey III  
Patent Attorney  
Registration Number 44,295

Attorney Docket Number I 2001.004 US  
Akzo Nobel Pharma Patent Department  
Intervet Inc.  
405 State Street  
P.O. Box 318  
Millsboro, DE 19966  
Tel. (302) 933-4034  
Fax (302) 934-4305

Supp Prelim Amend

4